1.35
-0.1(-6.90%)
Currency In USD
| Previous Close | 1.45 |
| Open | 1.38 |
| Day High | 1.43 |
| Day Low | 1.35 |
| 52-Week High | 36 |
| 52-Week Low | 1.26 |
| Volume | 52,240 |
| Average Volume | 104,988 |
| Market Cap | 3.85M |
| PE | -0.07 |
| EPS | -18.18 |
| Moving Average 50 Days | 1.97 |
| Moving Average 200 Days | 5.78 |
| Change | -0.1 |
If you invested $1000 in AIM ImmunoTech Inc. (AIM) 10 years ago, it would be worth $23.24 as of December 13, 2025 at a share price of $1.35. Whereas If you bought $1000 worth of AIM ImmunoTech Inc. (AIM) shares 5 years ago, it would be worth $754.19 as of December 13, 2025 at a share price of $1.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
GlobeNewswire Inc.
Dec 01, 2025 1:55 PM GMT
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, December 4th at 4:00 PM ETOCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today t
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
GlobeNewswire Inc.
Nov 18, 2025 1:55 PM GMT
OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a business update and reported its financial results for the third quarter 2025. “The third quarter was marked by solid
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
GlobeNewswire Inc.
Nov 10, 2025 1:55 PM GMT
OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing